ACER
Income statement / Annual
Last year (2022), Acer Therapeutics Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2022, Acer Therapeutics Inc.'s net income was -$27.86 M.
See Acer Therapeutics Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00
|
$1.26 M
|
$0.00
|
$0.00
|
$432,116.00
|
-$246,304.00
|
$2.91 M
|
$2.56 M
|
$1.27 M
|
$1.27 M
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$1.26 M |
$0.00 |
$0.00 |
$432,116.00 |
-$246,304.00 |
$2.91 M |
$2.56 M |
$1.27 M |
$1.27 M |
| Gross Profit Ratio |
0 |
1 |
0 |
0 |
1 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$11.92 M
|
$6.51 M
|
$11.85 M
|
$13.85 M
|
$12.45 M
|
$8.73 M
|
$6.50 M
|
$10.04 M
|
$12.12 M
|
$9.18 M
|
| General & Administrative
Expenses |
$12.69 M
|
$10.70 M
|
$10.95 M
|
$16.05 M
|
$9.26 M
|
$5.22 M
|
$3.12 M
|
$4.26 M
|
$3.83 M
|
$3.67 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$12.69 M
|
$10.70 M
|
$10.95 M
|
$16.05 M
|
$9.26 M
|
$5.22 M
|
$3.12 M
|
$4.26 M
|
$3.83 M
|
$3.67 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$10,629.00 |
$68,695.00 |
$2,147.00 |
$37,910.00 |
| Operating Expenses |
$24.61 M |
$17.21 M |
$22.80 M |
$29.90 M |
$21.71 M |
$13.95 M |
$9.86 M |
$14.65 M |
$16.34 M |
$13.19 M |
| Cost And Expenses |
$24.61 M |
$17.21 M |
$22.80 M |
$29.90 M |
$21.71 M |
$13.95 M |
$9.86 M |
$14.65 M |
$16.34 M |
$13.19 M |
| Interest Income |
$1,821.53 |
$49.27 |
$13,578.00 |
$471,267.00 |
$412,553.00 |
$14,848.00 |
$0.00 |
$0.00 |
$15,456.00 |
$14,985.00 |
| Interest Expense |
$101,432.00 |
$0.00 |
$0.00 |
$0.00 |
$987.00 |
$245,061.00 |
$0.00 |
$0.00 |
$1,983.00 |
$2.27 M |
| Depreciation &
Amortization |
-$198,470.00
|
-$54,757.00
|
$96,202.00
|
-$8,205.00
|
$27,744.00
|
$3,997.00
|
$238,127.00
|
$351,403.00
|
$387,779.00
|
$335,597.00
|
| EBITDA |
-$24.55 M
|
-$15.88 M
|
-$22.73 M
|
-$28.34 M
|
-$21.25 M
|
-$13.95 M
|
-$6.70 M
|
-$2.57 M
|
-$14.66 M
|
-$11.53 M
|
| EBITDA Ratio |
0 |
-12.7 |
0 |
0 |
-49.29 |
56.57 |
-1.95 |
-4.59 |
-11.53 |
-9.1 |
| Operating Income Ratio
|
0
|
-12.66
|
0
|
0
|
-50.25
|
56.63
|
-2.75
|
-4.73
|
-11.85
|
-9.41
|
| Total Other
Income/Expenses Net |
-$1.62 M
|
$574,396.00
|
-$82,624.00
|
-$1.02 M
|
$433,103.00
|
-$246,304.00
|
-$1.28 M
|
$74,606.00
|
$15,620.00
|
-$4.73 M
|
| Income Before Tax |
-$26.24 M |
-$15.37 M |
-$22.89 M |
-$29.42 M |
-$21.28 M |
-$14.19 M |
-$7.98 M |
-$12.02 M |
-$15.05 M |
-$16.66 M |
| Income Before Tax Ratio
|
0
|
-12.2
|
0
|
0
|
-49.25
|
57.63
|
-2.75
|
-4.7
|
-11.83
|
-13.15
|
| Income Tax Expense |
$1.62 M |
-$645,309.00 |
$11,810.00 |
-$537,754.00 |
-$432,116.00 |
$246,304.00 |
$1.04 M |
-$4,744.00 |
$4,130.00 |
$2.31 M |
| Net Income |
-$27.86 M |
-$14.73 M |
-$22.90 M |
-$28.88 M |
-$21.28 M |
-$14.19 M |
-$7.98 M |
-$12.02 M |
-$15.05 M |
-$16.66 M |
| Net Income Ratio |
0 |
-11.69 |
0 |
0 |
-49.25 |
57.63 |
-2.75 |
-4.7 |
-11.83 |
-13.15 |
| EPS |
-1.77 |
-1.03 |
-2.06 |
-2.86 |
-2.49 |
-3.84 |
-11.72 |
-21.26 |
-39.65 |
-91.56 |
| EPS Diluted |
-1.77 |
-1.03 |
-2.06 |
-2.86 |
-2.49 |
-3.84 |
-11.72 |
-21.26 |
-39.65 |
-91.56 |
| Weighted Average Shares
Out |
$15.77 M
|
$14.27 M
|
$11.12 M
|
$10.09 M
|
$8.56 M
|
$3.69 M
|
$680,668.00
|
$565,345.00
|
$379,627.00
|
$181,924.00
|
| Weighted Average Shares
Out Diluted |
$15.77 M
|
$14.27 M
|
$11.12 M
|
$10.09 M
|
$8.56 M
|
$3.69 M
|
$680,668.00
|
$565,345.00
|
$379,627.00
|
$181,924.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
